



St Helens and Knowsley  
Teaching Hospitals  
NHS Trust

Ref no: 017120118  
From: Commercial  
Date: 12/01/18  
Subject: Ophthalmology

**REQUEST**

Within your trust how many **intra-vitreous vials/implants** have been used in the latest 4 months, if possible between September to December 2017

Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

	<i>Lucentis (ranibizumab) Injections</i>	<i>Avastin (bevacizumab) Injections</i>	<i>Eylea (aflibercept) Injections</i>	<i>Illuvien (Fluocinolone) Implants</i>	<i>Ozudex (Dexamethasone) Implants</i>
<b>Total Vials / Implants</b>					
<i>Vials / Implants for Wet Age Related Macular Degeneration (wAMD)</i> <i>Vials / Implants for Diabetic Macular Oedema [DMO], Retinal Vein Occlusion [RVO] or other such as mVNV</i>					

## RESPONSE

The Pharmacy system cannot provide information of the indication being treated:  
The table below shows quantities issued September 2017 to December 2017

Data: JAC SCSUM

AFLIBERCEPT SOLUTION 40 mg/1ml Intravitreal Injection 0.1 mL Vial	452
BEVACIZUMAB (INTRAVITREAL) 5 mg/0.2ml Injection 1 syringe Pack	0
DEXAMETHASONE 700 microgram Intravitreal Implant 1 syringe Pack	33
RANIBIZUMAB 1.65 mg/0.165ml Pre-filled syringe 0.165 mL Pre-filled Syringe	473